Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Combined Dose-finding (Phase I) and Efficacy-finding (Phase II) Study of RO5323441 in Combination With Bevacizumab for Patients With Recurrent Glioblastoma

NCT01308684 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01308684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01308684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Combined Dose-finding (Phase I) and Efficacy-finding (Phase II) Study of RO5323441 in Combination With Bevacizumab for Patients With Recurrent Glioblastoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2011
Completion date
February 28, 2013
Enrollment
22 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme